Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 13, Issue 4, 2017, Pages 425-438

  Teschke, Rolf ^a,b   Danan, Gaby ^c  

^a Klinikum Hanau   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Pharmacovigilance Consultancy   (France)

Author keywords

alcoholic liver disease; antituberculous drugs; antiviral drugs; chronic liver disease; drug therapy; Drug induced liver injury (DILI); hepatitis B; hepatitis C; hepatitis E; liver cirrhosis; nonalcoholic fatty liver disease (NAFLD); Roussel Uclaf Causality Assessment Method (RUCAM); statins

Indexed keywords

ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PARACETAMOL; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL LIVER DISEASE; ALCOHOLIC FATTY LIVER; CASE STUDY; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; DRUG METABOLISM; DRUG TOLERABILITY; FATTY LIVER; HEPATITIS; HEPATITIS E; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; PREVALENCE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; TOXIC HEPATITIS; TUBERCULOSIS; VIRUS HEPATITIS; ANIMAL; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHRONIC DISEASE; COMPLICATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; LIVER DISEASE; PATHOPHYSIOLOGY;

ANIMALS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHRONIC DISEASE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; RISK FACTORS;

EID: 85015924555     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2017.1252749     Document Type: Review

References (97)

1. Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. Second Edition. Philadelphia (PA):Lippincott, Williams and Wilkins; 1999. Page 430•• Fundamental book on many potential hepatotoxins
2. Danan G, Bénichou C., Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings:application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–1330.•• Very first paper of a liver-specific method, called RUCAM (Roussel Uclaf Causality Assessment Method), to identify and score important items for causality grading of DILI, partially derived from an international consensus meeting
3. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs–II. An original model for validation of drug causality assessment methods:case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331–1336.• RUCAM validation with cases including positive rechallenge
4. Danan G, Teschke R. RUCAM in drug and herb induced liver injury:the update. Int J Mol Sci. 2016;17:14. DOI:10.3390/ijms17010014•• RUCAM update of 2016 for quantitative causality assessment using key items with individual scores.
5. Teschke R, Frenzel C, Wolff A, et al. Drug induced liver injury:accuracy of diagnosis in published reports. Ann Hepatol. 2014;13:248–255.• Listing compilation of missed competing diagnoses in published DILI cases.
6. Björnsson ES. Hepatotoxicity by drugs:the most common implicated agents. Int J Mol Sci. 2016;17:224. DOI:10.3390/ijms17020224•• Listing of important drugs causing DILI.
7. Hayashi PH. Drug-induced liver injury network:causality assessment, criteria, and experience in the United States. Int J Mol Sci. 2016;17:201. DOI:10.3390/ijms17020201•• Presents actual details of the DILIN method including its limitations, useful in comparison to RUCAM, see reference 4 above.
8. Teschke R, Andrade R. Editorial. Drug-induced liver injury:expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment. Gastroenterology. 2015;148:1271–1273. DOI:10.1053/j.gastro.2015.04.027.
9. Ortega-Alonso A, Stephens C, Lucena MI, et al. Case characterization, clinical features and risk factors in drug-induced liver injury. Int J Mol Sci. 2016;17:714. DOI:10.3390/ijms17050714• Comprehensive review of current DILI case characteristics.
10. Sarges P, Steinberg JM, Lewis JH. Drug-induced liver injury:highlights from a review of the 2015 literature. Drug Saf. 2016;39:561–575. DOI:10.1007/s4026401604278•• Critical review of DILI and HILI reports of 2015 with encouraging support on how to approach and improve case evaluations including causality assessments.
11. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries:a French population-based study. Hepatology. 2002;36:451–455.• One of the first studies assessing DILI epidemiology.
12. De Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury:population based case–control study. Br J Clin Pharmacol. 2004;58:71–80.
13. Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425.
14. Melchart D, Hager S, Dai J, et al. Quality control and complication screening programme of Chinese medicinal drugs at the first German hospital of traditional chinese medicine–A retrospective analysis. Forsch Komplementmed. 2016;23(2):21–28.• First exhaustive liver injury study of TCM from Germany.
15. Douros A, Bronder E, Andersohn F, et al. Herb-induced liver injury in the Berlin case-control surveillance study. Int J Mol Sci. 2016;17:114. DOI:10.3390/ijms17010114.
16. Teschke R, Larrey D, Melchart D, et al. Traditional Chinese medicine (TCM) and herbal hepatotoxicity:RUCAM and the role of novel diagnostic biomarkers such as microRNAs. Medicines. 2016;3:18. DOI:10.3390/medicines3030018• Detailed critical review of liver injury caused by herbal Traditional Chinese Medicine.
17. Frenzel C, Teschke R. Herbal hepatotoxicity:clinical characteristics and listing compilation. Int J Mol Sci. 2016;17:588. DOI:10.3390/ijms17050588.
18. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Sem Liver Dis. 2009;29:337–347.
19. Younossi ZM, Stepanova M, Affendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530.
20. Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States:A population-based study. J Clin Gastroenterol. 2015;49:690–696.
21. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58:388–396.• Balanced discussion of risk factors in DILI.
22. Yu K, Geng M, Zhang J, et al. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug induced liver injury. Drug Metab Dis. 2014;42:744–750.• Pointing to the role of high daily drug doses as risk factor of DILI.
23. Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury:search for signals. Hepatology. 2008;47:2003–2009.•• Importance of high daily drug dose as risk factor of DILI.
24. Lammert C, Bjornsson E, Niklasson A, et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse effects. Hepatology. 2010;51:615–620.• Balanced discussion on DILI risk factors based on a metabolic background.
25. Franz CC, Egger S, Born C, et al. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2012;68:179–188.• Discussing drug dosing in liver cirrhosis.
26. Lucena MI, Andrade RJ, Tognoni G, et al. Sanchez de la Cuesta F, and the Spanish group of therapeutic management in liver diseases drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2003;59:71–76.
27. Lewis JH, Stine JG. Review article:prescribing medications in patients with cirrhosis A practical guide. Aliment Pharmacol Ther. 2013;37:1132–1156.
28. Schlatterer-Häner C, Dose adaptation of drugs in patients with liver disease. Thesis University Basel, 2009. Available from:http://edoc.unibas.ch/926/1/Dose_Adaptation_of_Drugs_in_Patients_with_Liver_Disease.pdf. cited 2016 Jun20
29. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147–1161.
30. Delcò F, Tchambaz L, Schlienger R, et al. Drug adjustment in patients with liver disease. Drug Saf. 2005;28:529–545.
31. Branch RA, Herbert CM, Read AE. Determinants of serum antipyrine half-lives in patients with liver disease. Gut. 1973;14:569–573.
32. Merrell MD, Cherrington NJ. Drug metabolism in nonalcoholic fatty liver disease. Drug Metab Rev. 2011;43:317–334.• Basic discussion of drug metabolism in NAFLD.
33. Misra PS, Lefèvre A, Ishii H, et al. Increase of ethanol, meprobamate and pentobarbital after chronic ethanol administration in man and in rats. Am J Med. 1971;51:346–351.
34. Dyson JK, Hutchinson J, Harrison L, et al. Liver toxicity associated with sofobuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2016;64:234–238.
35. Gunaratnam NT, Benson J, Gandolfi AJ, et al. Suspected isoflurane hepatitis in an obese patient with a history of halothane hepatitis. Anesthesiology. 1995;83:1361–1364.
36. Tarantino G, Concha P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatology Res. 2007;37:410–415.•• One of the few prospective risk studies of DILI in pre-existing liver disease.
37. Nguyen GC, Sam J, Thuluvath PJ. Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States. Hepatology. 2008;48:1336–1341.
38. Fromenty B. Drug-induced liver injury in obesity. J Hepatology. 2013;58:824–826.
39. Yoon E, Babar A, Choudhary M, et al. Acetaminophen-induced hepatotoxicity:a comprehensive update. J Clin Translat Hepatol. 2016;4:131–142.• Thorough review of acetaminophen hepatotoxicity.
40. Safari S, Motavaf M, Siamdoust SAS, et al. Hepatotoxicity of halogenated inhalation anesthetics. Iran Red Crescent Med J. 2014;16(9):e20153.
41. Gaude GS, Chaudhury A, Hattiholi J. Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. J Family Med Prim Care. 2015;4:238–243. DOI:10.4103/2249-4863.154661.
42. Lee SS, Lee CM, Kim TH, et al. Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20:800–805. DOI:10.5588/ijtld.15.0668.
43. Kullak-Ublick GA, Merz M, Griffel L, et al. Liver safety assessment in special populations (hepatitis B, C, and oncology trials). Drug Saf. 2014;37(1):S57–S62.•• Stimulating suggestions how to diagnose flares of chronic virus hepatitis under antiviral drug therapy.
44. Wang NT, Huang YS, Lin MH, et al. Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury:Systematic review and meta-analysis. J Chin Med Assoc. 2016;79:368–374. DOI:10.1016/j.
45. Gupta NK, Lewis JH. Review article:the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther. 2008;28:1021–1041.
46. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Sem Liver Dis. 2009;29:337–347.
47. Kim WS, Lee SS, Lee CM, et al. Hepatitis C and not hepatitis B virus is a risk factor for anti-tuberculous drug induced liver injury. BMC Infectious Dis. 2016;16:50.
48. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26:1429–1435.•• First study showing importance of HEV exclusion in suspected DILI cases, a neglected topic.
49. Davern TJ, Chalasani N, Fontana RJ, et al. for the drug-induced liver injury network (DILIN) acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665–1672.
50. Chen EY, Baum K, Collins W, et al. Hepatitis E masquerading as drug–induced liver injury. Hepatology. 2012;56:2420–2423.
51. Begriche K, Massart J, Robin MA, et al. Drug-induced toxicity on mitochondria and lipid metabolism:mechanistic diversity and deleterious consequences for the liver. J Hepatol. 2011;54:773–794.
52. Aubert J, Begriche K, Knockaert L, et al. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease:Mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol. 2011;35:630–637.
53. Rabinowich L, Shibolet O. Drug induced steatohepatitis:An uncommon culprit of a common disease. BioMed Res Intern. 2015;2015:1–14. Article ID 168905. DOI:10.1155/2015/168905
54. Teschke R, Stutz G, Strohmeyer G. Increased paracetamol-induced hepatotoxicity after chronic alcohol consumption. Biochem Biophys Res Commun. 1979;91:368–374.
55. Teschke R, Stutz G, Moreno F. Cholestasis following chronic ethanol consumption:enhancement after an acute dose of chlorpromazine. Biochem Biophys Res Commun. 1980;94:1013–1020.
56. Hasumura Y, Teschke R, Lieber CS. Increased carbon tetrachloride hepatotoxicity, and its mechanism, after chronic ethanol consumption. Gastroenterology. 1974;66:415–422.
57. O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol. 2010;105:14–32.
58. Lieber CS. Cytochrome P-4502E1:its physiological and pathological role. Physiol Rev. 1997;77:517–544.•• Excellent review on importance of CYP2E1.
59. Roberts H, Kruszon-Moran D, Ly KN, et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households:National Health and Nutrition Examination Survey (NHANES), 1988-2012. Hepatology. 2016;63:388–397. DOI:10.1002/hep.28109.
60. Kowdley KV, Wang CC, Welch S, et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2012;56:422–433. DOI:10.1002/hep.24804.
61. Teschke R, Schulze J, Schwarzenboeck A, et al. Herbal hepatotoxicity:suspected cases assessed for alternative causes. Eur J Gastroenterol Hepatol. 2013;25:1093–1098. DOI:10.1097/MEG.0b013e3283603e89.
62. Teschke R, Schwarzenboeck A, Frenzel C, et al. The mystery of the Hawaii liver disease cluster in summer 2013:A pragmatic and clinical approach to solve the problem. Ann Hepatol. 2016;15:91–119. cited 2016 Jul8. Available from http://www.annalsofhepatology.com.mx/revista/numeros/2016/HP161-12-Mystery%20(web)%20(FF_041215V)_PROTEGIDO%20(1).pdf•• Critical assessment of suspected liver injury by a dietary supplement reported as cases from Honolulu.
63. Teschke R, Eickhoff A. The honolulu liver disease cluster at the medical center:its mysteries and challenges. Int J Mol Sci. 2016;17(4):476. DOI:10.3390/ijms17040476•• Summarized analysis of a suspected but not confirmed liver injury by a dietary supplement.
64. Heidemann LA, Navarro VJ, Ahmad J, et al. Severe acute hepatocellular injury attributed to oxyELITE pro:A case series. Dig Dis Sci. 2016;61:2741–2747. DOI:10.1007/s10620-016-4181-7.
65. Teschke R, Frenzel C. Drug induced liver injury:do we still need a routine liver biopsy for diagnosis today? Ann Hepatol. 2014;13:121–126.
66. Kleiner DE, Chalasani NP, Lee WM, et al. for the Drug-Induced Liver Injury Network (DILIN) hepatic histological findings in suspected drug-induced liver injury:systematic evaluation and clinical associations. Hepatology. 2014;59:661–670.
67. Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines of chronic hepatitis B. Hepatology. 2016;63:261–283.
68. Merz M, Lee KR, Kullak-Ublick GA, et al. Methodology to assess clinical liver safety data. Drug Saf. 2014;37(1):S33–S45.• Clinical recommendations to assess idiosyncratic DILI in clinical trials without the use of RUCAM.
69. Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B:pathogenesis, natural course, and management. J Hepatology. 2014;61:1407–1412.
70. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis virus (HCV)-infected persons in the United States:A multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521.
71. EASL. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
72. Teschke R, Danan G. Diagnosis and management of drug-induced liver injury (DILI) in patients with pre-existing liver disease. Drug Saf. 2016;39:729–744. DOI:10.1007/s40264-016-0423-z•• Suggestions on how to manage DILI in patients with pre-existing liver disease.
73. Hoofnagle JH, Nelson KE, Purcell RH. Review article:hepatitis E. N Engl J Med. 2012;367:1237–1244.•• Comprehensive overview on hepatitis E.
74. Kokki I, Smith D, Simmonds P, et al. Hepatitis E is the leading cause of acute viral hepatitis in Lothian, Scotland. New Microbe New Infect. 2016;10:6–12.
75. Centers for Disease Control and Prevention. Hepatitis E information. Hepatitis E FAQs for health professionals. cited 2015 Dec 18. Available from:http://www.cdc.gov/hepatitis/hev/hevfaq.htm. cited 2016 Jul8.
76. Teschke R, Schulze J, Eickhoff A, et al. Mysterious Hawaii liver disease case–Naproxen overdose as cause rather than oxyELITE pro? J Liver Clin Res. 2015;2. cited 2016 Jul8. Available from http://www.jscimedcentral.com/Liver/liver-2-1013.pdf• Example of an analytical approach of a suspected liver injury case.
77. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol. 2008;66:758–766.
78. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure:results of a United States multicentre, prospective study. Hepatology. 2005;42:1364–1372.
79. Myers RP, Shaheen AAM, Li B, et al. Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose. Clin Gastroenterol Hepatol. 2008;6:918–925.
80. Andrade RJ, Tulkens PM. Hepatic safety of antibiotics in primary care. Antimicrob Chemother. 2011;66:1431–1446.
81. Kramer JR, Giordano TP, Souchek J, et al. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol. 2005;42:309–314.
82. Bonacini M. Liver injury during highly active antiretroviral therapy:the effect of hepatitis C coinfection. Clin Infect Dis. 2004;38(Suppl 2):S104–S108.
83. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug–induced hepatotoxicity:the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871–1876.
84. Saukkonen JJ, Cohn DL, Jasmer RM, et al. on behalf of the ATS hepatotoxicity of antituberculosis therapy subcommittee an official ATS statement:hepatotoxicity of antituberculous therapy. Am J Crit Car Med. 2006;174:935–952.
85. Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000;31:201–206.
86. McGlynn KA, Lustbader ED, Sharrar RG, et al. Isoniazid prophylaxis in hepatitis B carriers. Am Rev Respir Dis. 1986;134:666–668.
87. Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol. 2002;97:1198–1203.
88. Wu JC, Lee SD, Yeh PF, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology. 1990;98:502–504.
89. Amarapurkar DN, Prabhudesai PP, Kalro RH, et al. Antituberculosis drug-induced hepatitis and HBsAg carriers. Tuberc Lung Dis. 1993;74:215–216.
90. Hwang SJ, Wu JC, Lee CN, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol. 1997;12:87–91.•• One of the few prospective studies on DILI risk in pre-existing liver disease.
91. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1278–1292.
92. Russo MW, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology. 2004;126:1477–1480.•• Stimulating discussion of a clinical relevant topic.
93. Chalasani N. Statins and hepatotoxicity:focus on patients with fatty liver. Hepatology. 2005;41:690–695.
94. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins:reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374–380.•• RUCAM-based assessment with causality verification in suspected statin hepatotoxicity.
95. Teschke R, Zhang L, Melzer L, et al. Green tea extract and the risk of drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2014;10:1663–1676. DOI:10.1517/17425255.2014.971011.
96. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 889 patients with drug- induced liver injury:the DILIN prospective study. Gastroenterology. 2015;148:1340–1352. DOI:10.1053/j.gastro.2015.03.00696.
97. Teschke R, Andrade RJ. Editorial of special issue “drug, herb, and dietary supplement hepatotoxicity. Int J Mol Sci. 2016;17:711.